The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Effects of Simvastatin and Oral Contraceptive Agent on Polycystic Ovary Syndrome: Prospective, Randomized, Crossover Trial
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is associated with hyperandrogenism and cardiovascular risks including dyslipidemia and systemic inflammation. In vitro, statins decrease proliferation and steroidogenesis of ovarian theca-interstitial cells. OBJECTIVE: The study objective was to compare effects of two treatments of PCOS: simvastatin plus oral contraceptive pill (OCP) vs. OCP alone. DESIGN: In a prospective, crossover trial, 48 women with PCOS were randomized to either simvastatin plus OCP for 12 wk followed by OCP alone for an additional 12 wk, or to OCP alone for 12 wk and, subsequently, simvastatin plus OCP for an additional 12 wk. Evaluations were performed at baseline, after 12 wk (crossover), and after 24 wk. Data were analyzed using a random effects model. SETTING: The study was conducted in an academic medical center. PRIMARY OUTCOME: Serum total testosterone was the primary outcome measure. RESULTS: Total testosterone decreased by 38% after Statin + OCP, whereas OCP alone led to a 26% decrease; the statin-attributable effect was significant (P < 0.004). Free testosterone declined by 58% after Statin + OCP, significantly more than the 35% decline after OCP alone (P = 0.006). Hirsutism decreased by 8.1% after Statin + OCP, a greater effect than the 4.7% decrease after OCP alone (P = 0.02). Statin decreased LH, but not FSH or prolactin. Statin + OCP decreased total and low-density lipoprotein cholesterol by 7.5% and 20%, respectively. OCP alone led to a 5% increase of total cholesterol without effect on low-density lipoprotein cholesterol. Statin prevented OCP induced increase of triglycerides. C-reactive protein decreased by 45% after Statin + OCP, a significantly different effect (P = 0.006) than a 6% increase after OCP alone. Soluble vascular cell adhesion molecule 1 decreased by 18% after Statin + OCP, a greater decline than the 10% decrease after OCP alone (P = 0.01). CONCLUSIONS: Simvastatin improved endocrine/clinical aspects of PCOS and had beneficial effects on lipid profile and markers of systemic inflammation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such medicines aid in decreasing low-grade inflammation that comes with PCOS, a condition where C-reactive protein levels are high [110].”
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yıldız, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,715
Clinical assessment of body hair growth in women.
Ferriman, D., & Gallwey, J. D. (1961) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jcem-21-11-1440 · Cited by 2,556
Ridker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
Men at risk: occupation and male infertility.
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,219
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis
Cybulsky, M. I., & Gimbrone, M. A. (1991) · Science · doi:10.1126/science.1990440 · Cited by 1,710
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–143 of 143
Xu, N., Taylor, K. D., Azziz, R., & Goodarzi, M. O. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.01.158 · Cited by 8
Effect of cholesterol biosynthesis inhibitor on some biochemical parameters in normal male rats
Kalo, M. S. (2009) · Al-mağallaẗ al-ʻirāqiyyaẗ li-l-ʻulūm al-bayṭariyyaẗ/Iraqi journal of veterinary sciences · doi:10.33899/ijvs.2009.5684 · Cited by 8
Zhao, J., Wang, R., Song, L., Han, H., Wang, P., Zhao, Y., Zhang, Y., & Zhang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1295412 · Cited by 7
Azargoon, A., Ghorbani, R., & Faraji, Z. (2013) · Europe PMC (PubMed Central) · Cited by 7
QSAR Model for Androgen Receptor Antagonism - Data from CHO Cell Reporter Gene Assays
Jensen, G. E. (2013) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.s2-006 · Cited by 6
Management of Dyslipidemia in Endocrine Diseases
Tannock, L. R. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.003 · Cited by 8
Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome
Barnes, R. B., Ehrmann, D. A., & Rosenfield, R. L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00132-5 · Cited by 6
Abdalla, M. A., Shah, N. Z., Deshmukh, H., Sahebkar, A., Östlundh, L., Al‐Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06549-6 · Cited by 4
Polycystic Ovary Syndrome, Inflammation, and Statins: Do We Have the Right Target?
Hoeger, K. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2376 · Cited by 4
Oral contraceptives in polycystic ovarian syndrome: the long and short of it
Nader, S. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.88 · Cited by 3
Metabolic dysfunctions in polycystic ovary syndrome
Rahman, M., Rahman, F. T., Mallik, M. U., Saha, J., Rahman, M. M., & Azad, K. A. K. (2024) · Journal of Medicine · doi:10.3329/jom.v25i1.70703 · Cited by 7
Mahilmaran, A., Chigullapalli, S., Parwani, P. J., Sharma, P., Senguttuvan, N. B., & Nayak, R. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_70_2025 · Cited by 3
Statins for women with polycystic ovary syndrome not actively trying to conceive
Xiong, T., Fraison, É., Kolibianaki, E., Costello, M., Venetis, C. A., & Kostova, E. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008565.pub3 · Cited by 2
Role of Statins in PCOS Management
Ortega, I., & Dulęba, A. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8394-6_11 · Cited by 2
Wheeler, C. J., Keye, W. R., & Peterson, C. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1436-1_11 · Cited by 2
Polycystic Ovary Syndrome: Update on Treatment Options and Treatment Considerations for the Future
Farrell-Turner, K. A. (2011) · Clinical Medicine Insights Women s Health · doi:10.4137/cmwh.s6715 · Cited by 3
Smith, J. W., & Taylor, J. S. (2011) · Nursing for Women s Health · doi:10.1111/j.1751-486x.2011.01664.x · Cited by 2
Polycystic ovary syndrome and cardiovascular disease risk
Legro, R. S. (2008) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-009-0011-1 · Cited by 2
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2023) · Pharmacology · doi:10.1159/000528939 · Cited by 2
Should we use statins in treatment of polycystic ovary syndrome?
Dulęba, A. J., & Pawelczyk, L. A. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.1 · Cited by 1
Self-citationRole of Statins and Resveratrol in PCOS Management
Sokalska, A., Ortega, I., & Dulęba, A. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_13 · Cited by 1
Statin therapy and sex hormones
Chiti, H., Parsamanesh, N., Reiner, Ž., Jamialahmadi, T., & Sahebkar, A. (2023) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-323-88534-8.00012-2 · Cited by 1
Effect of Two Combined Oral Contraceptives on Serum Lipid Profile
Mustafa, M. T. G., Zabeen, S., Monirujjaman, M., & Bashar, T. (2014) · Bangladesh Medical Journal · doi:10.3329/bmj.v40i3.18679 · Cited by 1
Rosuvastatin Add On Metformin In The Treatment Of Polycystic Ovarian Syndrome
Al-Gareeb, A. I., Mohammad, B. I., Abd-Alamieer, W. S., & Al-Mayahi, T. J. (2017) · AL-QADISIYAH MEDICAL JOURNAL · doi:10.28922/qmj.2015.11.19.47-53 · Cited by 1
Faryal, U., Jadoon, M., Shoukat, S., Ahmad, A., Rashid, S., & Shaheen, R. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023171767 · Cited by 1
Visceral fat and cardiovascular risk in patients with polycystic ovary syndrome
Cascella, T., Palomba, S., Giallauria, F., de Sio, I., Colao, A., Lombardi, G., Orio, M., & Orio, F. (2009) · Clinical Lipidology · doi:10.2217/clp.09.55 · Cited by 1
The use of Simvastatin Plus Metformin Therapy in Patients With Polycystic Ovarian Syndrome
Carrick, E. (2012) · CommonKnowledge Research Repository (Pacific University Oregon)
Mejía-Montilla, J. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Análise comparativa dos sistemas de aspiração traqueal aberto e fechado
de Carvalho, W. B., & Johnston, C. (2007) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302007000200005
Estatinas na síndrome dos ovários policísticos
Aldrighi, A. P. S., & Aldrighi, J. M. (2007) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302007000200006
Tratamiento del síndrome de ovario poliquístico: Anticonceptivos orales
Cabrera, M., Centeno, I., & Nottola, N. (2007) · Revista Venezolana de Endocrinología y Metabolismo
Dardzińska, J. A., & Rachoń, D. (2012) · Endokrynologia, Otyłość i Zaburzenia Przemiany Materii
Renke, M. (2009)
Oral contraceptives: indications and cautions
Nader, S. (2013) · doi:10.2217/ebo.12.238
PROLACTIN AND HYPERPROLACTINAEMIA IN FEMALE REPRODUCTIVE ENDOCRINOLOGY – AN UPDATE
Kutlesic, R. M., Popović, J., Stefanović, M., Vukomanović, P., Milošević, J., & Stanišić, D. M. (2021) · Facta Universitatis Series Medicine and Biology · doi:10.22190/fumb200902007k
(2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3282f37e31
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282fba8b4
(2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832c937e
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f4f084
Aru, N., Yang, C., Chen, Y., & Liu, J. (2025) · Medicine · doi:10.1097/md.0000000000042685
Zahn, L. A., Budine, T. D., Shirey-Rice, J. K., Joly, M. M., Wallis, R. S., Bernard, G. R., Holroyd, K. J., Pulley, J. M., & Jerome, R. N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1562587
The impact of phytochemicals on statin efficacy and safety: A review
Vatankhah, P., Alamdari-Palangi, V., Kian, M., Hosseinpour-Soleimani, F., Savardshtaki, A., Tajbakhsh, A., & Hashempur, M. H. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179129
Metadata
- Authors
- Banaszewska, B., Pawelczyk, L., Spaczynski, R. Z., Dziura, J., & Duleba, A. J.
- Affiliations
- Poznan University of Medical Sciences (PL)
- Department of Gynecology/Obstetrics (B.B., L.P., R.Z.S.), Poznan University of Medical Sciences, 60-535 Poznan, Poland
- Yale University (US)
- Department of Obstetrics and Gynecology (A.J.D.), Yale University School of Medicine, New Haven, Connecticut 06520
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-11-14
- Volume
- 92
- Issue
- 2
- Pages
- 456-461
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1995813378
- Cited by
- 143
- References
- 51
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 12 · 2012: 8
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hd040207-04)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD40207)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
- Keywords
- polycystic ovary syndrome, simvastatin, oral contraceptives, hyperandrogenism, testosterone, free testosterone, hirsutism, luteinizing hormone, cholesterol, triglycerides, C-reactive protein, soluble vascular cell adhesion molecule-1, inflammation, cardiovascular risk, statins, theca-interstitial cells, ovarian steroidogenesis, dyslipidemia
- MeSH terms
- Adult, Hypolipidemic Agents, Contraceptives, Oral, Combined, Drug Therapy, Combination, Estrogens, Ethinyl Estradiol, Female, Humans, Pituitary Hormones, Polycystic Ovary Syndrome, Prospective Studies, Testosterone, Treatment Outcome, Desogestrel, Cross-Over Studies, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review